Priming treatment with T-cell redirecting bispecific antibody ERY974 reduced cytokine induction without losing cytotoxic activity in vitro by changing the chromatin state in T cells

Iwata, Y., Narushima, Y., Harada, A. and Mishima, M. Priming treatment with T-cell redirecting bispecific antibody ERY974 reduced cytokine induction without losing cytotoxic activity in vitro by changing the chromatin state in T cells. Toxicology And Applied Pharmacology. 2022; 441, 115986. doi: 10.1016/j.taap.2022.115986

Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer – The VIABLE Phase 3 Randomized Clinical Trial

Vogelzang, N. J., Beer, T. M., Gerritsen, W., Oudard, S., Wiechno, P., Kukielka-Budny, B., Samal, V., Hajek, J., Feyerabend, S., Khoo, V., Stenzl, A., Csöszi, T., Filipovic, Z., Goncalves, F., Prokhorov, A., Cheung, E., Hussain, A., Sousa, N., Bahl, A., Hussain, S., Fricke, H., Kadlecova, P., Scheiner, T., Korolkiewicz, R. P., Bartunkova, J., Spisek, R., […]

CRISPR single base editing, neuronal disease modelling and functional genomics for genetic variant analysis: pipeline validation using Kleefstra syndrome EHMT1 haploinsufficiency

Fear, V. S., Forbes, C. A., Anderson, D., Rauschert, S., Syn, G., Shaw, N., Jamieson, S., Ward, M., Baynam, G. and Lassmann, T. CRISPR single base editing, neuronal disease modelling and functional genomics for genetic variant analysis: pipeline validation using Kleefstra syndrome EHMT1 haploinsufficiency. Stem Cell Research & Therapy. 2022; 13(1). doi: 10.1186/s13287-022-02740-3